View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Catalent
6 September 2017

Catalent to Manufacture Opiod Discontinuation Treatment Iofexidine

Catalent Pharma Solutions has announced it has entered an exclusive agreement with US WorldMeds for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

US WorldMeds has the rights to commercialise lofexidine in the US, which is currently approved as Britlofex™ in the United Kingdom. Catalent and US WorldMeds have worked together to successfully tech transfer the manufacturing from a facility overseas to Catalent’s facility in Winchester, Kentucky. There, the company has produced registration batches to support US WorldMeds’ new drug application (NDA) to the US Food and Drug Administration (FDA) and the anticipated commercial launch.

Lofexidine received fast track designation by the FDA, a process designed to expedite the review of drugs that treat serious conditions and address an unmet medical need. If approved, lofexidine would be the first non-narcotic and non-addictive medication in the US for treatment of symptoms associated with opioid withdrawal.

Catalent ‎vice-president and general manager of drug delivery solutions said: "Symptoms of opioid withdrawal can be a significant barrier in seeking help and breaking the cycle of dependence and addiction.

"We are excited to join forces with US WorldMeds to bring a potential new treatment option to a major health issue spanning the nation."

Catalent’s Winchester facility has more than 20 years’ experience in product development, technology transfer, and commercial manufacturing. The site has produced more than three billion tablets and capsules annually and launched more than 100 new products into the market since its inception.

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology